LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc. (LUCD) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.05 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.3% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer.
Sector
Healthcare
Industry
Medical Instruments/Supply